Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. develops oral recombinant pill vaccines based on a proprietary delivery platform. The clinical-stage biotechnology company’s programs include vaccine candidates for coronavirus, norovirus and influenza, as well as a therapeutic human papillomavirus vaccine as its first immune-oncology indication. Its pill-based vaccines are designed for oral administration, storage and shipping without refrigeration, and avoidance of needle-stick risk.
Vaxart news centers on clinical data and scientific publications, business updates, financial results, financing arrangements, collaborations, intellectual property around adenovirus and TLR3 agonist oral vaccination technology, and governance changes as the company advances its oral vaccine pipeline.
Vaxart, Inc. (NASDAQ: VXRT) announced positive top-line results from the Phase II study of its COVID-19 oral vaccine candidate, VXA-CoV2-1.1-S. The study achieved primary safety and secondary immunogenicity endpoints, showing significant increases in serum neutralizing antibodies, particularly in subjects previously vaccinated with mRNA. Approximately 50% of participants exhibited cross-reactive mucosal responses to Omicron variants. Vaxart aims to advance new vaccine constructs for clinical trials by mid-2023, highlighting the potential for an effective oral COVID-19 vaccine.
Vaxart, Inc. (Nasdaq: VXRT) announced the release of top-line data from the first part of its two-part COVID-19 Phase II trial for its Wuhan S-only construct, scheduled for September 1, 2022. The company will host a live conference call and webcast at 8:30 a.m. ET on the same day to discuss the findings. Interested analysts and investors can participate via designated phone lines. Vaxart is focused on developing oral recombinant vaccines, with a range of programs aimed at various viral diseases, leveraging its innovative tablet delivery platform.
Vaxart, Inc. (NASDAQ: VXRT) has appointed Dr. Ray Stapleton as its Chief Technology Officer (CTO), effective immediately. With over 20 years of experience, Dr. Stapleton previously worked at Genocea, focusing on personalized immunotherapies. Vaxart's CEO, Andrei Floroiu, expressed confidence in Dr. Stapleton's ability to enhance the company's oral vaccine development efforts. Dr. Stapleton has a strong background in manufacturing operations, having held significant roles at Merck and American Type Culture Collection. Vaxart is developing innovative oral vaccines for various diseases, aiming to change global vaccination methods.
Vaxart, Inc. (NASDAQ: VXRT) announced the appointment of Elaine J. Heron, Ph.D., to its Board of Directors, effective August 25, 2022. With extensive experience in life sciences, Dr. Heron has held various leadership roles, including CEO of Amplyx Pharmaceuticals and Labcyte Inc. Heron replaces Dr. Julie Cherrington, who stepped down from the board. Dr. Heron will contribute to the Science and Technology and Audit Committees, bringing valuable insights to Vaxart's strategic direction as it develops oral vaccines targeting diseases such as coronavirus and RSV.
Vaxart, Inc. (NASDAQ: VXRT) reported progress in its COVID-19 and norovirus vaccine programs in its second quarter update on August 8, 2022. They are developing vaccine candidates targeting omicron variants and expect top-line Phase II COVID-19 data in Q3 2022. The company ended Q2 with $131.5 million in cash, down from $157.0 million, and reported a net loss of $29.4 million. R&D expenses surged to $19.9 million, reflecting increased investments in vaccine development. The company aims to select COVID-19 constructs in Q4 2022 and start new trials in 2023.
Vaxart, Inc. (Nasdaq: VXRT) announced that all six proposals in its 2022 Proxy Statement were approved at the reconvened Annual Meeting of Stockholders on August 4, 2022. Proposal 2, which increases the authorized shares to 250 million, received 82% support, surpassing the required 50%. Proposals 3 and 4, amendments to the Equity Incentive Plan and the Employee Stock Purchase Plan, were contingent on the passage of Proposal 2. This strong backing reflects stockholder confidence in Vaxart's oral vaccine programs.
Vaxart, Inc. (NASDAQ: VXRT) announced it will report its Q2 2022 financial results on August 8, 2022, after market close. A conference call hosted by senior management will begin at 4:30 p.m. ET to provide a business update and discuss financials. Vaxart is a clinical-stage biotech company focused on developing oral recombinant vaccines for various diseases, including coronavirus and norovirus. The company utilizes a unique tablet delivery system, aiming to enhance vaccine accessibility and safety.
Vaxart, Inc. (Nasdaq: VXRT) announced its request for stockholders to vote on Proxy Proposal #2, which aims to increase authorized shares to 250 million. As of now, 49.1% of shares have voted in favor, needing an additional 0.9% for approval by the August 3, 2022, deadline. Notably, over 80% of the votes cast so far support the proposal, with backing from leading proxy advisory firms ISS and Glass Lewis. CEO Andrei Floroiu emphasized the proposal's importance for business growth and competitive positioning.
Vaxart's recent phase 1 clinical trial data reveals its Spike/Nucleocapsid (S+N) oral tablet COVID-19 vaccine induces long-lasting mucosal IgA antibody responses, with effects lasting up to one year. These IgA antibodies exhibited greater neutralizing activity than those from convalescent samples. The study involved 35 healthy participants and confirmed the vaccine's tolerability and immunogenicity. Vaxart aims to leverage these findings for future vaccine candidate development as part of ongoing efforts to address emerging SARS-CoV-2 variants.
Vaxart, Inc. (Nasdaq: VXRT) announced that its Chief Scientific Officer, Dr. Sean Tucker, and Senior Scientist, Dr. Rebecca Flitter, will present data on its COVID-19 oral tablet vaccine at the International Congress of Mucosal Immunology 2022, scheduled for July 16-20 in Seattle. On July 18, Dr. Tucker will discuss oral vaccination's ability to induce pan-coronavirus nasal IgA responses, while Dr. Flitter will present findings on mucosal rAd5 immunization against SARS-CoV-2, showcasing its effectiveness in non-human primates.